The Geneva Patient: HIV Remission Without the Protective Mutation
The story
Skip to the verdict ↓A man the doctors call Romuald had carried HIV for more than thirty years when, in 2018, an aggressive blood cancer forced a stem-cell transplant on him in Geneva. His new immune system came from a donor — but not the rare, HIV-resistant kind that had freed the handful of patients cured before him. In 2021, watching closely, his doctors took him off his antiretroviral drugs anyway.
In the medical literature he is the Geneva patient, and the virus he has carried is HIV-1. The cancer was an extramedullary myeloid tumor, a form of myeloid sarcoma, and the transplant it forced — allogeneic hematopoietic stem cells — was performed at Geneva University Hospitals (HUG) in Switzerland. The withdrawal of his antiretroviral medication came in November 2021, under close monitoring.
As reported in Nature Medicine in September 2024, his plasma viral load remained undetectable for 32 months afterward, with no rebound — a span now approaching three years off all treatment.
The detail that set this case apart was the donor. The handful of people previously considered cured or in long-term remission after such transplants — the Berlin, London, Düsseldorf, New York, and City of Hope patients — all received cells carrying a rare genetic variant called CCR5-delta32, which removes the doorway HIV uses to enter cells. Romuald's donor was an unrelated, nine-of-ten HLA-matched man with no CCR5-delta32 mutation at all. In the laboratory, his new immune cells remain fully susceptible to HIV infection.
The study was led by Professor Asier Sáez-Cirión of the Institut Pasteur and Professor Alexandra Calmy of HUG and the University of Geneva, working through an international consortium (IciStem). The patient is recorded in the primary report as a 53-year-old male, study ID IciS-34. The researchers state that they do not know what is holding the virus in check, and put forward several hypotheses: that the donor's innate immune cells carry unusually strong anti-HIV activity; that graft-versus-host reactions during engraftment cleared the latent viral reservoir; and that the immunosuppressant ruxolitinib, used to manage those reactions, may have helped suppress reactivation. The team describes the outcome as "remission" rather than "cure," noting that a late viral rebound, even years out, remains biologically possible.
The same patient, donor genetics, timeline, and proposed mechanisms are reported across the Nature Medicine paper (published September 2, 2024), an Institut Pasteur press release, and secondary science-press coverage. Institut Pasteur states that seven individuals worldwide are considered cured or in long-term remission after such transplants.
It happened — and nature accounts for it.
Reviewer Notes
Miracles Jar weighs each claim two ways — how extraordinary it would be, and how strong the evidence is.
Assessed by Miracles Jar AI
Documented, mechanism unexplained
The verdict: "Documented, mechanism unexplained." Filed as a case where nature's ordinary mechanisms seem to fall short — explicitly NOT a supernatural claim. This is an unexplained-anomaly entry, not a violation-of-nature claim. A known, well-understood cure mechanism (CCR5Δ32-driven HIV resistance) is absent here, and the operative mechanism remains scientifically open.
Why this is an "open mechanism" case rather than a solved one
By the prevailing model — in which the CCR5-delta32 mutation was understood to be the decisive ingredient — the virus should have rebounded once it was clear the donor cells lacked that mutation and remained susceptible in the lab. It has not. That gap between expectation and outcome is what makes this an honest open-mechanism case. The authors are admirably candid that they do not know what is suppressing the virus, and the three hypotheses they float (donor innate-immune anti-HIV activity; graft-versus-host clearance of the reservoir; ruxolitinib suppression) are each plausible but none yet confirmed. It is scientifically appropriate to call this "remission" rather than "cure" — a single late rebound would reframe the story, and the researchers say so themselves.
How a reader should hold this
The facts are about as solid as medical evidence gets — a top-tier peer-reviewed journal, named investigators at world-class institutions, an international consortium (IciStem), longitudinal viral-load data, and an internally consistent account echoed by the institutions' own press materials. The evidence is very strong; the mechanism is the genuinely open question. This is not a debunk (nothing is fabricated or exaggerated) and not a declared miracle (a natural biological explanation almost certainly exists and is being actively hunted). It is, precisely, a documented surprise. For someone living with HIV, that is a quietly hopeful thing — a sign that the paths to durable remission may be wider than science assumed.
Evidence ledger — what the verdict rests on
Published in Nature Medicine (Sept 2024), one of the top peer-reviewed medical journals, with named senior authors at the Institut Pasteur and University of Geneva / HUG.
Objective, hard endpoint: plasma viral load remained undetectable for 32 months after antiretroviral therapy was deliberately interrupted in November 2021 — a measurable, monitored outcome, not patient self-report.
The donor was an unrelated 9/10 HLA-matched male with wild-type CCR5 (no CCR5Δ32). The patient's reconstituted cells are confirmed still susceptible to HIV in the lab — so the standard known cure mechanism is genuinely absent here.
Corroborated across independent sources: the journal paper, the Institut Pasteur institutional release, and secondary science press all report the same patient, donor genetics, and timeline.
Plausible natural explanations are explicitly on the table — donor innate-immune anti-HIV activity, graft-versus-host clearance of the viral reservoir, and ruxolitinib immunosuppression. A biological mechanism almost certainly exists; it is simply not yet pinned down.
This is 'remission,' not a declared cure. A late viral rebound, even years out, remains biologically possible and would change the characterization — the researchers themselves are cautious on this point.
What would raise the meter: Long-term follow-up documenting permanence, in a condition with a near-zero spontaneous-resolution base rate, would raise the meter.
What would lower it: A documented relapse, or case literature showing the condition fluctuates or remits on its own, would move it down.
How we weigh every claim — the full method, deductions and all →
The natural explanation
The leading natural account for this case is spontaneous remission & the body's own recovery. Read what it explains — and where it stops.
Sources
Tagged by proximity to the event. Primary sources are direct or contemporaneous; tertiary are downstream retellings.
- 1.Primaryacademic
Peer-reviewed primary report. Confirms 53-year-old male patient (study ID IciS-34), >30 years living with HIV-1, allo-HSCT for extramedullary myeloid tumor, unrelated 9/10 HLA-matched donor with no CCR5Δ32 mutation, and undetectable viral load for 32 months after ART interruption. States control mechanisms remain unclear; flags allogeneic immunity and ruxolitinib as candidate factors.
- 2.Primaryother
Official institutional press release (used here as a primary institutional source, not a religious document). Confirms patient nickname 'Romuald,' wild-type CCR5 donor, remission nearly three years after stopping ART, the three proposed mechanisms, leads Calmy (HUG/Univ. Geneva) and Sáez-Cirión (Institut Pasteur), and that seven individuals worldwide are considered cured/in long-term remission after such transplants. Publication date September 2, 2024.
- 3.Secondarynews
Science-news coverage corroborating the same facts: 'Romuald, the Geneva patient,' wild-type CCR5 donor leaving his cells susceptible to HIV, nearly three years off ART, and the three candidate mechanisms. Contrasts with Berlin/London cases where CCR5-delta32 was decisive.
Cases like this
Nearest on the map — similar in how miraculous they’d be, and how strong the evidence is.